Evaxion A (EVAX) Total Liabilities (2019 - 2026)
Evaxion A's (EVAX) quarterly Total Liabilities came in at $10.4 million in Q1 2026, down 29.95% YoY from $14.9 million in Q1 2025, and down 8.22% on a QoQ basis from $11.4 million in Q4 2025.
Evaxion A (EVAX) Total Liabilities (2019 - 2026) Analysis & Trends
Evaxion A (EVAX) has 8 years of Total Liabilities data on file, last reported at $10.4 million in Q1 2026.
- Quarterly Total Liabilities fell 29.95% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 29.95% YoY) and the FY2025 annual result came in at $11.4 million, down 19.58% from the prior year.
- Total Liabilities declined to $10.4 million in Q1 2026, from $11.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $16.2 million in Q2 2025 to a low of $20050.0 in Q1 2024.
- A 5-year average of $9.6 million and a median of $13.5 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities sank 99.86% — and 2025, when it jumped 74194.26%.
- Tracing EVAX's Total Liabilities over 5 years: stood at $573000.0 in 2022, then plunged by 66.84% to $190000.0 in 2023, then surged by 7340.53% to $14.1 million in 2024, then retreated by 19.58% to $11.4 million in 2025, then dropped by 8.22% to $10.4 million in 2026.
- The last three Total Liabilities figures came in at $10.4 million (Q1 2026), $11.4 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 10.03 Bn |
| 10 | Evaxion A | 27.06 Mn | 27.06 Mn | - | 10.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.44 Mn |
| Dec 31, 2025 | 11.37 Mn |
| Sep 30, 2025 | 13.14 Mn |
| Jun 30, 2025 | 16.22 Mn |
| Mar 31, 2025 | 14.90 Mn |
| Dec 31, 2024 | 14.14 Mn |
| Jun 30, 2024 | 48,000.00 |
| Mar 31, 2024 | 20,050.00 |
| Dec 31, 2023 | 190,000.00 |
| Sep 30, 2023 | 14.68 Mn |
| Jun 30, 2023 | 14.22 Mn |
| Mar 31, 2023 | 13.91 Mn |
| Dec 31, 2022 | 573,000.00 |
| Sep 30, 2022 | 13.90 Mn |
| Jun 30, 2022 | 625,000.00 |
| Mar 31, 2022 | 14.69 Mn |
| Dec 31, 2021 | 7.73 Mn |
| Sep 30, 2021 | 7.47 Mn |
| Jun 30, 2021 | 5.83 Mn |
| Mar 31, 2021 | 7.12 Mn |